CY1109257T1 - Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων - Google Patents

Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων

Info

Publication number
CY1109257T1
CY1109257T1 CY20091100595T CY091100595T CY1109257T1 CY 1109257 T1 CY1109257 T1 CY 1109257T1 CY 20091100595 T CY20091100595 T CY 20091100595T CY 091100595 T CY091100595 T CY 091100595T CY 1109257 T1 CY1109257 T1 CY 1109257T1
Authority
CY
Cyprus
Prior art keywords
peptide
dna sequence
polypeptide
juv
similar
Prior art date
Application number
CY20091100595T
Other languages
Greek (el)
English (en)
Inventor
Arvind Devshi Varsani
Edward Peter Rybicki
Original Assignee
University Of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109257(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University Of Cape Town filed Critical University Of Cape Town
Publication of CY1109257T1 publication Critical patent/CY1109257T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20091100595T 2002-05-17 2009-06-04 Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων CY1109257T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200203957 2002-05-17
EP03727750A EP1506222B2 (en) 2002-05-17 2003-05-19 Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide, virus-like particles prepared therefrom and a method for preparing the particles

Publications (1)

Publication Number Publication Date
CY1109257T1 true CY1109257T1 (el) 2014-07-02

Family

ID=29550639

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100595T CY1109257T1 (el) 2002-05-17 2009-06-04 Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων

Country Status (13)

Country Link
US (2) US7407807B2 (enExample)
EP (1) EP1506222B2 (enExample)
JP (2) JP4614765B2 (enExample)
AT (1) ATE424409T1 (enExample)
AU (1) AU2003232951B2 (enExample)
CA (1) CA2486450C (enExample)
CY (1) CY1109257T1 (enExample)
DE (1) DE60326449D1 (enExample)
DK (1) DK1506222T3 (enExample)
ES (1) ES2323634T5 (enExample)
PT (1) PT1506222E (enExample)
SI (1) SI1506222T1 (enExample)
WO (1) WO2003097673A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228715D0 (en) * 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
CN101166827B (zh) 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN103890177B (zh) * 2011-12-01 2016-03-09 开普敦大学 Hpv嵌合颗粒
WO2015009853A1 (en) * 2013-07-16 2015-01-22 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
WO2015192018A1 (en) 2014-06-12 2015-12-17 Iowa Approach Inc. Method and apparatus for rapid and selective tissue ablation with cooling
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
EP1728800A1 (de) * 1994-10-07 2006-12-06 Loyola University Of Chicago Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6228368B1 (en) † 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19812941A1 (de) † 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor
US6926897B1 (en) † 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE69933875T2 (de) * 1998-08-14 2007-05-31 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
GB9921146D0 (en) † 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP2416798B1 (en) † 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines

Also Published As

Publication number Publication date
US20060035319A1 (en) 2006-02-16
US8163557B2 (en) 2012-04-24
EP1506222B2 (en) 2012-05-23
CA2486450A1 (en) 2003-11-27
AU2003232951A1 (en) 2003-12-02
JP4614765B2 (ja) 2011-01-19
EP1506222B1 (en) 2009-03-04
US7407807B2 (en) 2008-08-05
PT1506222E (pt) 2009-06-12
ATE424409T1 (de) 2009-03-15
WO2003097673A2 (en) 2003-11-27
AU2003232951B2 (en) 2009-07-23
EP1506222A2 (en) 2005-02-16
DE60326449D1 (de) 2009-04-16
ES2323634T5 (es) 2012-09-04
WO2003097673B1 (en) 2004-04-22
WO2003097673A3 (en) 2004-03-18
CA2486450C (en) 2013-11-19
SI1506222T1 (sl) 2009-10-31
US20090047302A1 (en) 2009-02-19
ES2323634T3 (es) 2009-07-22
DK1506222T3 (da) 2009-07-06
JP2010263899A (ja) 2010-11-25
JP2006507797A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
MXPA05005051A (es) Vacuna de vector adenoviral.
DK1618888T3 (da) Fremstilling af humant papillomvirus-capsidprotein og viruslignende partikler
MXPA03009354A (es) Un clon infeccioso de adnc del virus del sindrome reproductivo y respiratorio porcino (prrs) norteamericano y sus usos.
MXPA05010007A (es) Replicones de alfavirus y construcciones auxiliares mejorados.
DE69834671D1 (de) Immunantwort gegen HPV Antigene hervorgerufen von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einem Expressionsvektor fähig zur Expression dieser Proteine
BRPI0417509A (pt) molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira
DE69535018D1 (de) Papillomavirus vakzine
ATE369428T1 (de) Behandlung von gebärmutterhalskrebs
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
DK1506222T3 (da) Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne
WO2002081709A3 (en) Modified hpv e6 and e7 genes and proteins useful for vaccination
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
HUP0304053A2 (hu) Új expressziós vektorok és azok alkalmazása
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
TW200509964A (en) VP1 of foot-and-mouth disease virus
CO5580837A2 (es) Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirus
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
SE0002498D0 (sv) Papillomavirus vaccine
ATE380863T1 (de) Neue, aus bacillus licheniformis stammende aminopeptidase, die aminopeptidase codierendes gen, das gen enthaltender expressionsvektor, transformant sowie verfahren zur herstellung davon
FR2859221B1 (fr) Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations